Following the approval of vamorolone as a Duchenne muscular dystrophy treatment for use in NHS England and NHS Scotland, DMD Care UK hosted a webinar on 13 March to give the latest information about vamorolone to help the community to understand what this means for DMD treatment.
The webinar provided an opportunity for questions and answers with clinician experts and representatives from Action Duchenne, Duchenne UK, MDUK.
You can watch the webinar here.
DMD Care UK has also published a summary of available evidence on vamorolone, which can be downloaded here
Full guidelines for families on all corticosteroid treatment in DMD (covering prednisolone, deflazacort and vamorolone) will be available from DMD Care UK in April.
If you have any questions, or would feel you need support regarding the topics discussed in this webinar, please reach out to us at info@actionduchenne.org
